Pan Changyu, Ji Linong, Lu Juming, Yang Wenying, Zhou Zhiguang
Department of Endocrinology, Chinese PLA General Hospital, Beijing 100853, China; Email:
Zhonghua Nei Ke Za Zhi. 2015 Jul;54(7):612-7.
To evaluate the effectiveness and safety on once-daily (OD) insulin detemir (IDet) in Chinese patients with type 2 diabetes mellitus (T2DM) who were treated with different types or combinations of oral anti-diabetic drugs (OADs).
The SOLVE™ study was a 24-week observational study on the initiation of IDet OD in T2DM patients with uncontrolled hyperglycemia on diet, exercise, and one or more OADs. Subjects were grouped based on the numbers of OADs taken before (>2-OAD, 2-OAD, and 1-OAD groups). Efficacy and safety endpoints were evaluated and compared in different groups.
This study includes 3 272 patients, among them 464 (14.2%) were treated with more than 2 OADs, 1511 (46.2%) with 2 OADs, and 1 218 (37.2%) with 1 OAD before the study. The mean glycosylated hemoglobin A1c (HbA1c) was 8.4%, 8.3%, 8.4% at baseline, and 7.3%, 7.2%, 7.1% at the end of 24-week in each 3 groups (all P<0.001 vs. baseline values). The HbA1c reductions were not statistically significant different among groups. Body weight tended to decrease in patients from all groups, however, only that in the 2-OAD group reached statistically significance. No major hypoglycaemia events were reported. However, the overall minor hypoglycaemia rate in the 2-OAD group was higher at the end of the study than that at baseline (P<0.05). No differences in the rate of nocturnal minor hypoglycaemia were observed in all groups after IDet treatment.
Initiation of IDet OD was effective and well-tolerated in Chinese patients with T2DM whose glycemia was poorly controlled on OADs irrespective of the number of OADs taken before. (registration number NCT00825643).
评估一日一次(OD)地特胰岛素(IDet)在中国2型糖尿病(T2DM)患者中的有效性和安全性,这些患者接受不同类型或组合的口服抗糖尿病药物(OADs)治疗。
SOLVE™研究是一项为期24周的观察性研究,针对饮食、运动及一种或多种OADs治疗后血糖控制不佳的T2DM患者起始使用IDet OD治疗。根据研究前服用OADs的数量对受试者进行分组(>2种OADs组、2种OADs组和1种OADs组)。对不同组的疗效和安全性终点进行评估和比较。
本研究纳入3272例患者,其中研究前464例(14.2%)接受超过2种OADs治疗,1511例(46.2%)接受2种OADs治疗,1218例(37.2%)接受1种OADs治疗。三组患者基线时糖化血红蛋白A1c(HbA1c)均值分别为8.4%、8.3%、8.4%,24周结束时分别为7.3%、7.2%、7.1%(与基线值相比,P均<0.001)。各组间HbA1c降低幅度无统计学显著差异。所有组患者体重均有下降趋势,但仅2种OADs组达到统计学显著水平。未报告严重低血糖事件。然而,研究结束时2种OADs组总体轻度低血糖发生率高于基线时(P<0.05)。IDet治疗后所有组夜间轻度低血糖发生率无差异。
对于OADs治疗后血糖控制不佳的中国T2DM患者,无论之前服用OADs的数量多少,起始使用IDet OD均有效且耐受性良好。(注册号NCT00825643)